Research Article

Relationship between the expression of Notch1 and EZH2 and the prognosis of breast invasive ductal carcinoma

Published: March 22, 2016
Genet. Mol. Res. 15(1): gmr7464 DOI: https://doi.org/10.4238/gmr.15017464
Cite this Article:
L. Zhao, Q.Y. Zhang, X. Luan, X. Huang, S. Zhao, H. Zhao, L. Zhao, Q.Y. Zhang, X. Luan, X. Huang, S. Zhao, H. Zhao, L. Zhao, Q.Y. Zhang, X. Luan, X. Huang, S. Zhao, H. Zhao (2016). Relationship between the expression of Notch1 and EZH2 and the prognosis of breast invasive ductal carcinoma. Genet. Mol. Res. 15(1): gmr7464. https://doi.org/10.4238/gmr.15017464
3,897 views

Abstract

We determined whether the coexpression of Notch1 and EZH2 influences the progression and prognosis of breast invasive ductal carcinoma. Using the χ2 test, a significant difference was found between high and low expression of Notch1 in terms of lymph node, hormone receptor, and p53 expression (P < 0.05). Moreover, a significant difference was found between high and low expression of EZH2 in terms of tumor size, histologic grade, hormone receptor, and expression of Ki67 (P < 0.05). Using Pearson correlation analysis, we found a significant positive correlation between Notch1 and EZH2 expression in the tissue samples of breast invasive ductal carcinoma (P = 0.038). High Notch1 and EZH2 expression was associated with poor progression-free survival compared with low expression (PNotch1 = 0.000, 40.3 vs 48.9 months; PEZH2 = 0.000, 40.2 vs 49.9 months). Moreover, we found that high Notch1 and EZH2 expression was associated with poor overall survival compared with low expression (PNotch1 = 0.000, 51.2 vs 56.2 months; PEZH2 = 0.002, 51.7 vs 56.4 months). In conclusion, Notch1 and EZH2 coexpression contributes to the progression and prognosis of breast invasive ductal carcinoma.

We determined whether the coexpression of Notch1 and EZH2 influences the progression and prognosis of breast invasive ductal carcinoma. Using the χ2 test, a significant difference was found between high and low expression of Notch1 in terms of lymph node, hormone receptor, and p53 expression (P Notch1 = 0.000, 40.3 vs 48.9 months; PEZH2 = 0.000, 40.2 vs 49.9 months). Moreover, we found that high Notch1 and EZH2 expression was associated with poor overall survival compared with low expression (PNotch1 = 0.000, 51.2 vs 56.2 months; PEZH2 = 0.002, 51.7 vs 56.4 months). In conclusion, Notch1 and EZH2 coexpression contributes to the progression and prognosis of breast invasive ductal carcinoma.